Geert R A M D'Haens (G D'Haens, Geert R D'Haens, Geert D'Haens)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 27

Top Topics

Ulcerative Colitis

Top Venues

Inflammatory bowel diseases

Journal of Crohn's & colitis

Alimentary pharmacology & therapeutics

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Bruce E Sands, Geert R A M D'Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory bowel diseases (2024)
Sara van Gennep, Ivan C N Fung, Djuna C de Jong, Rishand K Ramkisoen, Esmé Clasquin, Jitteke de Jong, Leonie C S de Vries, Wouter J de Jonge, Krisztina B Gecse, Mark Löwenberg, John C Woolcott, Aart Mookhoek, Geert R A M D'Haens
Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib. Journal of Crohn's & colitis 18 (8) (2024)
Bruce E Sands, Geert R A M D'Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory bowel diseases (2024)
Geert R A M D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, Bruce E Sands, Scott Lee, Richard E Moses, Isabel Redondo, Rodrigo Escobar, Theresa Hunter Gibble, Anthony Keohane, Nathan Morris, Xin Zhang, Vipin Arora, Taku Kobayashi
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials. Inflammatory bowel diseases (2024)
Sara van Gennep, Ivan C N Fung, Djuna C de Jong, Rishand K Ramkisoen, Esmé Clasquin, Jitteke de Jong, Leonie C S de Vries, Wouter J de Jonge, Krisztina B Gecse, Mark Löwenberg, John C Woolcott, Aart Mookhoek, Geert R A M D'Haens
Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib. Journal of Crohn's & colitis 18 (8) (2024)
Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, Julian Panes, Stefan Schreiber, Walter Reinisch, Brian G Feagan, Silvio Danese, Andres J Yarur, Geert R A M D'Haens, Martina Goetsch, Karolina Wosik, Michael Keating, Krisztina Lazin, Joseph Wu, Irene Modesto, Aoibhinn McDonnell, Lauren Bartolome, Severine Vermeire
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. Journal of Crohn's & colitis 18 (8) (2024)
Walter Reinisch, Jean-Frederic Colombel, Geert R A M D'Haens, Jordi Rimola, Tomasz Masior, Matt McKevitt, Xuehan Ren, Adrian Serone, David A Schwartz, Krisztina B Gecse
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial. Journal of Crohn's & colitis 18 (6) (2024)
Carlos G Gonzalez, Toer W Stevens, Bram Verstockt, David J Gonzalez, Geert R A M D'Haens, Parambir S Dulai
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab. Inflammatory bowel diseases (2024)
Walter Reinisch, Jean-Frederic Colombel, Geert R A M D'Haens, Jordi Rimola, Tomasz Masior, Matt McKevitt, Xuehan Ren, Adrian Serone, David A Schwartz, Krisztina B Gecse
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial. Journal of Crohn's & colitis 18 (6) (2024)
Walter Reinisch, Jean-Frederic Colombel, Geert R A M D'Haens, Jordi Rimola, Tomasz Masior, Matt McKevitt, Xuehan Ren, Adrian Serone, David A Schwartz, Krisztina B Gecse
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial. Journal of Crohn's & colitis 18 (6) (2024)
Reena Khanna, Brian G Feagan, Guangyong Zou, Larry W Stitt, John W D McDonald, Brian Bressler, Remo Panaccione, Lisa M Shackelton, Tanja VanViegen, Edward V Loftus, Marco Daperno, Vipul Jairath, Geert R A M D'Haens, William J Sandborn
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease. Inflammatory bowel diseases (2024)
Carlos G Gonzalez, Toer W Stevens, Bram Verstockt, David J Gonzalez, Geert R A M D'Haens, Parambir S Dulai
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab. Inflammatory bowel diseases (2024)
Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, Julian Panes, Stefan Schreiber, Walter Reinisch, Brian G Feagan, Silvio Danese, Andres J Yarur, Geert R A M D'Haens, Martina Goetsch, Karolina Wosik, Michael Keating, Krisztina Lazin, Joseph Wu, Irene Modesto, Aoibhinn McDonnell, Lauren Bartolome, Severine Vermeire
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. Journal of Crohn's & colitis 18 (8) (2024)
Carlos G Gonzalez, Toer W Stevens, Bram Verstockt, David J Gonzalez, Geert R A M D'Haens, Parambir S Dulai
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab. Inflammatory bowel diseases 30 (9) (2024)
Suzanne I Anjie, Melanie S Hulshoff, Geert R A M D'Haens
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand? Expert opinion on biological therapy (2023)
Geert R A M D'Haens, Walter Reinisch, Stefan Schreiber, Fraser Cummings, Peter M Irving, Byong Duk Ye, Dong-Hyeon Kim, Sangwook Yoon, Shomron Ben-Horin
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial. Clinical drug investigation (2023)
Ruben J Colman, Tomoyuki Mizuno, Keizo Fukushima, David B Haslam, Jeffrey S Hyams, Brendan Boyle, Joshua D Noe, Geert R A M D'Haens, Johan E Van Limbergen, Kelly Chun, Jane Yang, Lee A Denson, Nicholas J Ollberding, Alexander A Vinks, Phillip Paul Minar
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Alimentary pharmacology & therapeutics (2022)
Marc Ferrante, Peter M Irving, Christian Philipp Selinger, Geert R A M D'Haens, Tanja Kuehbacher, Ursula E Seidler, Savion Gropper, Thomas Haeufel, Sebastiano Forgia, Silvio Danese, Jochen Klaus, Brian G Feagan
Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert opinion on drug safety (2022)
Jurij Hanžel, Melanie S Hulshoff, Joep Grootjans, Geert R A M D'Haens
Emerging therapies for ulcerative colitis. Expert review of clinical immunology 18 (5) (2022)
Leanne J Kosse, Gerda Weits, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Martijn Bastiaan Adriaan van Doorn, Phyllis I Spuls, Geert R A M D'Haens, Michael T Nurmohamed, Eugene P van Puijenbroek, Bart Jf Van Den Bemt, Naomi T Jessurun
Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert opinion on drug safety 20 (12) (2021)
Xavier Roblin, Adrian Serone, Oh Kyu Yoon, Luting Zhuo, Ethan Grant, Jacky Woo, Jinfeng Liu, René Galien, Geert R A M D'Haens
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's Disease. Inflammatory bowel diseases (2021)
Geert R A M D'Haens, Sander van Deventer
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 70 (7) (2021)
Adriaan Volkers, Peter Bossuyt, Jitteke de Jong, Lieven Pouillon, Krisztina Gecse, Marjolijn Duijvestein, Cyriel Ponsioen, Geert R A M D'Haens, Mark Löwenberg
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study. Scandinavian journal of gastroenterology 57 (4) (2021)
HoUng Kim, Rieke E Alten, J R Fraser Cummings, Silvio Danese, Geert R A M D'Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, Jong Hyuk Lee, James O Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven R A Simoens, René Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs 13 (1) (2021)
Edward V Loftus, Brian G Feagan, Remo Panaccione, Jean Frederic Colombel, William J Sandborn, Bruce E Sands, Silvio Danese, Geert R A M D'Haens, David T Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A Lirio, Severine Vermeire
Long-term safety of vedolizumab for inflammatory bowel disease. Alimentary pharmacology & therapeutics 52 (8) (2020)
Geert R A M D'Haens, James O Lindsay, Remo Panaccione, Stefan Schreiber
Ulcerative Colitis: Shifting Sands. Drugs in R&D 19 (2) (2019)
Christopher Ma, Leonardo Guizzetti, R Panaccione, Richard N Fedorak, Rish K Pai, C E Parker, T M Nguyen, R Khanna, Niels Vande Casteele, Geert R A M D'Haens, William J Sandborn, Brian G Feagan, Vipul Jairath
Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Alimentary pharmacology & therapeutics 47 (12) (2018)